GET DAILY SIGNALSCardinal Health (CAH) Shares Advance +11.3% on Contract Renewal and Analyst Upgrades
Key Takeaways
- Cardinal Health (CAH) shares climbed roughly 11.3% over the past 30 days, moving from about $228 to near $254.
- The advance accelerated in early October after the company extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032.
- Management reaffirmed fiscal 2027 non-GAAP EPS guidance of 13%–15% growth ($12.40–$12.60), reinforcing confidence in the earnings trajectory.
- Analysts lifted price targets during the period, including Mizuho (to $280) and UBS (to $295), while reiterating Buy or Outperform ratings.
- A roughly $2.7 billion Defense Logistics Agency contract award for the Medical Surgical Prime Vendor program added to positive sentiment.
- First-quarter fiscal 2027 results, due November 5, represent the next major catalyst, with consensus EPS near $2.92–$2.95.
- For deeper detail on valuation, results, and expectations, explore Cardinal Health's Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Cardinal Health (CAH) Company Overview and Market Position
Cardinal Health, Inc. is a diversified healthcare services and products company headquartered in Dublin, Ohio. It operates primarily through two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company distributes branded and generic pharmaceuticals, specialty drugs, and over-the-counter healthcare products, while also supplying medical, surgical, and laboratory products to hospitals, pharmacies, physician offices, and other care settings.
Investors follow CAH for its scale in the healthcare supply chain, its expanding high-margin specialty and at-home businesses, and its consistent earnings growth. In fiscal 2026, Cardinal Health generated approximately $254 billion in revenue, reflecting double-digit year-over-year growth. The company's breadth across pharmaceutical distribution and medical products, combined with initiatives in specialty, nuclear medicine, and at-home solutions, positions it as one of the largest healthcare distributors in the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cardinal Health (CAH) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, Cardinal Health shares advanced about 11.3%, rising from a closing level near $228 in early October to approximately $254 in early November. The move outpaced the broader market and the medical sector over the same stretch, underscoring the stock's relative strength.
The trailing three-month picture is more measured. From the start of August, when shares traded near $235, the stock has gained roughly 8%. The path has been uneven: shares consolidated through August, pulled back into the low $220s by late September, and then rebounded sharply in October as positive contract and analyst developments accumulated. The recent rally effectively reversed the September weakness and pushed CAH toward the upper end of its 52-week range.
What Drove CAH Stock Price in the Last 30 Days
The most significant catalyst was Cardinal Health's announcement on October 1 that it had entered a binding Letter of Intent to extend its existing pharmaceutical distribution agreement with CVS Health (CVS) through June 30, 2032. The extension removed a key overhang tied to one of the company's largest customer relationships. In connection with the renewal, Cardinal Health reaffirmed its fiscal 2027 non-GAAP EPS guidance of 13%–15% growth ($12.40–$12.60), and shares rose on the news.
Analyst activity reinforced the positive tone. Mizuho raised its price target to $280 from $250 while maintaining an Outperform rating, and UBS lifted its target to $295 from $280 with a Buy rating. Bank of America characterized the CVS contract extensions as a "clearing event" for the drug distribution group, reiterating Buy ratings on Cardinal Health and peer McKesson (MCK).
Additional support came from a roughly $2.7 billion contract award from the Defense Logistics Agency for the Medical Surgical Prime Vendor program. These catalysts, combined with solid underlying demand in pharmaceutical distribution and specialty solutions, helped sustain the rally into early November. From what I see, the contract news was the clearest driver here.
What Drove CAH Stock Performance Over the Last Quarter
Over the trailing quarter, Cardinal Health's stock performance reflected a broader narrative of resilient demand and improving visibility on key customer contracts. August began with the company reporting fourth-quarter fiscal 2026 results that beat earnings expectations, with adjusted EPS of $2.91 versus a consensus near $2.42, while full-year revenue grew double digits.
A September pullback reflected broader market choppiness and profit-taking after a strong run, with shares retreating from the mid-$240s into the low $220s. The October contract extension with CVS Health, reaffirmed guidance, and rising analyst price targets then re-established an upward trend. Underpinning the move was management's confidence in double-digit specialty growth and 2%–3% generics volume growth, which together support the company's long-term earnings growth algorithm.
CAH Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is Cardinal Health's first-quarter fiscal 2027 earnings report on November 5, before the market opens. Analysts project adjusted EPS near $2.92–$2.95 on revenue of roughly $66–67 billion. Given the company's record of beating EPS estimates in eight consecutive quarters, guidance updates and commentary on specialty growth will be closely watched.
Beyond earnings, investors should monitor pharmaceutical utilization trends, specialty and at-home segment momentum, the integration of recent acquisitions, and the evolving regulatory environment around drug pricing and 340B. Macroeconomic factors, including tariff and commodity cost pressures in the medical products segment, also remain relevant. These factors will help shape the stock's path through the remainder of fiscal 2027. I’m watching this closely as the next earnings release approaches.
How Tickeron AI Tools Fit Into My Research
In my own work, I often turn to Tickeron’s AI Trading Bots to test how different automated strategies might respond to setups like the one unfolding with CAH. The platform lets me review performance across various timeframes and approaches, which helps me cross-check ideas without replacing my own analysis. It is one more data point in a broader process, and I find it useful when evaluating momentum in healthcare names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CAH turns positive, indicating new upward trend
CAH saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 65 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 47 cases where CAH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 264 of 396 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 22 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Moving Average Convergence Divergence Histogram (MACD) for CAH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 26 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.428) is normal, around the industry mean (12.613). CAH has a moderately high P/E Ratio (34.983) as compared to the industry average of (10.633). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.138) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement